Nureca Limited has informed the Exchange regarding Outcome of Board Meeting
NURECA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Nureca Limited reported FY26 revenue of ₹1,472.10 million, up 28.4% from ₹1,146.40 million in FY25, with full-year PAT turning positive at ₹2.97 million versus a loss of ₹6.68 million. However, Q4 FY26 showed a significant loss of ₹66.25 million due to a ₹83.37 million fair value loss on FVTPL investments. The company approved ₹100 crore incremental capex for manufacturing medical devices and healthcare products at its Derabassi facility, plus land purchase for future expansion. CFO Mr. Naresh Gupta resigned for better career opportunities and will be replaced by Mr. Chander Kant (promoted internally). The board also approved related-party director re-appointments (Aryan Goyal as CEO, Saurabh Goyal as MD, and new appointment of Smita Goyal as Whole-time Director), all subject to shareholder approval at the July 28, 2026 AGM. Auditors issued an unmodified (clean) opinion.
Revenue growth of 28.4% is positive, but the Q4 loss driven by investment mark-to-market losses may concern investors in the short term. The related-party management appointments and CFO transition warrant monitoring. The capex approval signals expansion but will require capital deployment.